Pelthos Therapeutics Inc.
PTHSNYSECIK 1919246HealthcareFiscal year ends Dec 31
Reports and events: 67 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-3009:17 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-120457 |
| 2026-10-0117:15 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001919246-26-000125 |
| 2026-08-1817:00 ET | DEF 14A | Proxy statementPeriod 2026-09-29 | 0001919246-26-000120 |
| 2026-08-1307:20 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001919246-26-000113 |
| 2026-08-1307:15 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000112 |
| 2026-08-1307:06 ET | 10-Q/A | Quarterly report, amendedPeriod 2026-03-31 | 0001919246-26-000111 |
| 2026-08-1307:00 ET | 8-K | 4.02 Non-reliance on financial statements | 0001919246-26-000110 |
| 2026-05-2817:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000085 |
| 2026-05-2117:00 ET | 8-K | 4.01 Change of auditor; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001919246-26-000078 |
| 2026-05-1407:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000071 |
| 2026-05-1407:06 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001919246-26-000070 |
| 2026-04-1408:42 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000060 |
| 2026-04-1017:04 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000058 |
| 2026-03-1906:39 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001919246-26-000014 |
| 2026-03-1906:37 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001919246-26-000013 |
| 2026-01-1308:30 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-26-000097 |
| 2026-01-1216:31 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001753926-26-000094 |
| 2026-01-0216:46 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-26-000010 |
| 2025-12-2317:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-25-001964 |
| 2025-12-1716:15 ET | 8-K | 5.07 Shareholder vote results | 0001753926-25-001906 |
| 2025-11-2508:30 ET | DEF 14A | Proxy statementPeriod 2025-12-17 | 0001753926-25-001827 |
| 2025-11-1306:50 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-25-001766 |
| 2025-11-1306:46 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001753926-25-001764 |
| 2025-11-0708:01 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-25-001715 |
| 2025-10-1407:46 ET | 8-K | 7.01 Regulation FD disclosure | 0001753926-25-001606 |
| 2025-09-1616:10 ET | 8-K/A | 2.01 Completion of an acquisition or disposition; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001753926-25-001500 |
| 2025-09-0308:31 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-25-001425 |
| 2025-08-1808:05 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-25-001353 |
| 2025-08-1316:39 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001753926-25-001326 |
| 2025-07-0321:07 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001753926-25-001081 |
| 2025-07-0217:22 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-25-001055 |
| 2025-05-1316:31 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001753926-25-000790 |
| 2025-05-0117:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-25-000722 |
| 2025-04-1706:11 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 4.01 Change of auditor; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-25-000652 |
| 2025-03-2717:08 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001753926-25-000503 |
| 2025-03-0307:00 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001753926-25-000376 |
| 2024-11-2109:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-24-001983 |
| 2024-11-1817:03 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001753926-24-001955 |
| 2024-11-1316:30 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001753926-24-001883 |
| 2024-10-2408:30 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-24-001759 |
| 2024-09-2617:08 ET | DEF 14A | Proxy statementPeriod 2024-10-22 | 0001140361-24-042069 |
| 2024-08-1316:31 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001753926-24-001423 |
| 2024-08-0716:50 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-24-001376 |
| 2024-07-2909:15 ET | S-1 | Registration statement | 0001753926-24-001279 |
| 2024-07-2909:06 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-24-001275 |
| 2024-05-1516:06 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001753926-24-000976 |
| 2024-04-1616:48 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001753926-24-000740 |
| 2024-04-0908:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-24-000691 |
| 2024-03-2109:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001753926-24-000584 |
| 2024-03-1816:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001753926-24-000550 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 30, 2026, 16:23 ET. Listed shows no prices and gives no investment advice.